MONT-SAINT-GUIBERT, Belgium, November 12, 2013 -- /PRNewswire/ -- Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces:
A business update for the nine-month period ending 30 September 2013
Help employers find you! Check out all the jobs and post your resume.
